AR117621A2 - UNA SOLUCIÓN ACUOSA SIN ALCOHOL ETÍLICO QUE COMPRENDE UN b-BLOQUEANTE Y DISPOSITIVO - Google Patents
UNA SOLUCIÓN ACUOSA SIN ALCOHOL ETÍLICO QUE COMPRENDE UN b-BLOQUEANTE Y DISPOSITIVOInfo
- Publication number
- AR117621A2 AR117621A2 ARP190102095A ARP190102095A AR117621A2 AR 117621 A2 AR117621 A2 AR 117621A2 AR P190102095 A ARP190102095 A AR P190102095A AR P190102095 A ARP190102095 A AR P190102095A AR 117621 A2 AR117621 A2 AR 117621A2
- Authority
- AR
- Argentina
- Prior art keywords
- blocker
- aqueous solution
- ethyl alcohol
- alcohol including
- propranolol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Seasonings (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Una solución acuosa sin alcohol etílico, que comprende un b-bloqueante, un edulcorante de tipo no azucarado y que está sustancialmente libre de un agente conservante aromático. Él se selecciona de un b-bloqueante no selectivo, por ejemplo de alprenolol, bucindolol, carteolol, carvedilol, labetalol, levobunolol, medroxalol, mepindolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propafenona, propranolol, sotalol, timolol y sales farmacéuticamente aceptables de los mismos y, por ejemplo, propranolol o una sal farmacéuticamente aceptable del mismo, y está presente en una cantidad de 0,001 a 5% p/V, por ejemplo de 0,01 a 1% p/V.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09290298A EP2246044A1 (en) | 2009-04-21 | 2009-04-21 | Paediatric solutions comprising a beta-blocker |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117621A2 true AR117621A2 (es) | 2021-08-18 |
Family
ID=40940328
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101299A AR076338A1 (es) | 2009-04-21 | 2010-04-20 | Disoluciones pediatricas para beta-bloqueantes |
| ARP190102095A AR117621A2 (es) | 2009-04-21 | 2019-07-25 | UNA SOLUCIÓN ACUOSA SIN ALCOHOL ETÍLICO QUE COMPRENDE UN b-BLOQUEANTE Y DISPOSITIVO |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101299A AR076338A1 (es) | 2009-04-21 | 2010-04-20 | Disoluciones pediatricas para beta-bloqueantes |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US20120035270A1 (es) |
| EP (4) | EP2246044A1 (es) |
| JP (1) | JP5695029B2 (es) |
| KR (1) | KR101713866B1 (es) |
| CN (1) | CN102405041A (es) |
| AR (2) | AR076338A1 (es) |
| AU (1) | AU2010240551B2 (es) |
| BR (1) | BRPI1015447B1 (es) |
| CA (1) | CA2755175C (es) |
| CL (1) | CL2011002634A1 (es) |
| CO (1) | CO6410278A2 (es) |
| CY (2) | CY1119390T1 (es) |
| DK (2) | DK2421504T4 (es) |
| ES (2) | ES2685178T5 (es) |
| GE (1) | GEP20146087B (es) |
| HR (2) | HRP20170610T4 (es) |
| HU (2) | HUE039937T2 (es) |
| IL (1) | IL214674A (es) |
| LT (2) | LT2421504T (es) |
| MA (1) | MA33003B1 (es) |
| MX (1) | MX337463B (es) |
| NZ (1) | NZ594592A (es) |
| PL (2) | PL2497461T5 (es) |
| PT (2) | PT2497461T (es) |
| RS (2) | RS57668B2 (es) |
| RU (1) | RU2011139233A (es) |
| SG (1) | SG172960A1 (es) |
| SI (2) | SI2497461T2 (es) |
| TN (1) | TN2011000350A1 (es) |
| TW (1) | TWI429459B (es) |
| UA (1) | UA107570C2 (es) |
| WO (1) | WO2010122442A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2246044A1 (en) | 2009-04-21 | 2010-11-03 | Pierre Fabre Dermo-Cosmétique | Paediatric solutions comprising a beta-blocker |
| SI3287123T1 (sl) | 2011-03-04 | 2020-07-31 | Gruenenthal Gmbh | Vodna farmacevtska formulacija tapentadola za peroralno uporabo |
| JP2019142972A (ja) * | 2011-03-04 | 2019-08-29 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | タペンタドールの非経口的投与 |
| SI2680833T1 (sl) * | 2011-03-04 | 2016-06-30 | Gruenenthal Gmbh | Parenteralno dajanje tapentadola |
| US9724297B2 (en) * | 2014-04-01 | 2017-08-08 | Arbor Pharmaceuticals, Inc. | Sotalol compositions and uses of the same |
| MX2017012312A (es) | 2015-03-27 | 2018-01-18 | Gruenenthal Gmbh | Formulacion estable para administracion parenteral de tapentadol. |
| BR112019005439A2 (pt) | 2016-09-23 | 2019-06-18 | Gruenenthal Gmbh | formulação estável para administração parenteral de tapentadol |
| CN108261411B (zh) * | 2016-12-30 | 2021-04-30 | 武汉科福新药有限责任公司 | 用于婴幼儿血管瘤治疗的口腔膜剂及其制备方法 |
| CN107320467A (zh) * | 2017-07-21 | 2017-11-07 | 江苏云阳集团药业有限公司 | 一种盐酸普萘洛尔药用组合物及其制备方法 |
| CN108299279B (zh) * | 2018-02-09 | 2021-03-23 | 北京梅尔森医药技术开发有限公司 | 取代芳基胺醇化合物及其制备方法和用途 |
| US11547123B2 (en) * | 2019-08-16 | 2023-01-10 | The Folger Coffee Company | Methods for reducing negative flavor attributes in coffee and compositions therefrom |
| EP4223283A1 (en) | 2020-09-30 | 2023-08-09 | Nissan Chemical Corporation | Water-soluble complex containing beta- blocker and lecithin |
| CN118021718B (zh) * | 2024-04-12 | 2024-07-02 | 成都瑞尔医药科技有限公司 | 一种盐酸普罗帕酮注射液及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4600708A (en) | 1985-07-19 | 1986-07-15 | American Home Products Corporation | Propranolol hydrochloride liquid formulations |
| HU209251B (en) * | 1992-03-13 | 1994-04-28 | Synepos Ag | Process for producing stable, peroral solution drug forms with controlled release of active ingredient and comprising beta-blocking pharmacons |
| EP0732064B1 (en) | 1995-03-15 | 2001-06-06 | Kao Corporation | Use of a bitterness relieving agent |
| JPH1025253A (ja) * | 1996-07-12 | 1998-01-27 | Kao Corp | 苦味低減化剤及び苦味低減化法 |
| JPH11349492A (ja) * | 1998-06-03 | 1999-12-21 | Yamanouchi Pharmaceut Co Ltd | 苦味を低減した経口用医薬組成物および苦味低減化方法 |
| JP2001342151A (ja) * | 2000-03-31 | 2001-12-11 | Eisai Co Ltd | 甘味を有する薬剤組成物 |
| NZ529173A (en) * | 2001-05-25 | 2005-07-29 | Warner Lambert Co | Stable liquid pharmaceutical composition comprising a GABA analog i.e. gabapentin or pregabalin, and a polyhydric alcohol e.g. glycerol, xylitol, sorbitol, mannitol |
| EP1543831A1 (en) * | 2003-12-18 | 2005-06-22 | Pfizer GmbH Arzneimittelwerk Gödecke | Pregabalin composition |
| WO2006093493A1 (en) * | 2005-02-25 | 2006-09-08 | Biomarin Pharmaceutical Inc. | Room temperature stable aqueous liquid pharmaceutical composition |
| EP1888030A1 (en) * | 2005-05-25 | 2008-02-20 | Janssen Pharmaceutica N.V. | Pediatric formulation of topiramate |
| DE102006020604A1 (de) * | 2006-05-02 | 2007-11-08 | Bayer Healthcare Ag | Flüssige Arzneimittelformulierung |
| EP2050441A1 (en) | 2007-10-19 | 2009-04-22 | Université Victor Segalen Bordeaux 2 | Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
| SI2268282T1 (sl) * | 2008-04-25 | 2015-01-30 | Apotex Technologies Inc. | Tekoča farmacevtska oblika deferiprona s prijetnim okusom |
| EP2246044A1 (en) | 2009-04-21 | 2010-11-03 | Pierre Fabre Dermo-Cosmétique | Paediatric solutions comprising a beta-blocker |
-
2009
- 2009-04-21 EP EP09290298A patent/EP2246044A1/en not_active Withdrawn
-
2010
- 2010-04-12 SI SI201031741T patent/SI2497461T2/sl unknown
- 2010-04-12 PL PL12155472T patent/PL2497461T5/pl unknown
- 2010-04-12 CA CA2755175A patent/CA2755175C/en active Active
- 2010-04-12 EP EP12155472.9A patent/EP2497461B2/en active Active
- 2010-04-12 DK DK10717263.7T patent/DK2421504T4/da active
- 2010-04-12 PL PL10717263.7T patent/PL2421504T5/pl unknown
- 2010-04-12 PT PT12155472T patent/PT2497461T/pt unknown
- 2010-04-12 SG SG2011050663A patent/SG172960A1/en unknown
- 2010-04-12 NZ NZ594592A patent/NZ594592A/xx unknown
- 2010-04-12 RS RS20181036A patent/RS57668B2/sr unknown
- 2010-04-12 KR KR1020117024721A patent/KR101713866B1/ko active IP Right Grant
- 2010-04-12 LT LTEP10717263.7T patent/LT2421504T/lt unknown
- 2010-04-12 AU AU2010240551A patent/AU2010240551B2/en active Active
- 2010-04-12 PT PT107172637T patent/PT2421504T/pt unknown
- 2010-04-12 RU RU2011139233/15A patent/RU2011139233A/ru unknown
- 2010-04-12 BR BRPI1015447A patent/BRPI1015447B1/pt active IP Right Grant
- 2010-04-12 GE GEAP201012468A patent/GEP20146087B/en unknown
- 2010-04-12 EP EP10717263.7A patent/EP2421504B2/en active Active
- 2010-04-12 HU HUE12155472A patent/HUE039937T2/hu unknown
- 2010-04-12 MA MA34064A patent/MA33003B1/fr unknown
- 2010-04-12 JP JP2012506607A patent/JP5695029B2/ja active Active
- 2010-04-12 DK DK12155472.9T patent/DK2497461T4/da active
- 2010-04-12 ES ES12155472T patent/ES2685178T5/es active Active
- 2010-04-12 SI SI201031439A patent/SI2421504T1/sl unknown
- 2010-04-12 HR HRP20170610TT patent/HRP20170610T4/hr unknown
- 2010-04-12 US US13/265,739 patent/US20120035270A1/en not_active Abandoned
- 2010-04-12 EP EP18174428.5A patent/EP3384899A1/en active Pending
- 2010-04-12 RS RS20170358A patent/RS55862B2/sr unknown
- 2010-04-12 HU HUE10717263A patent/HUE034581T2/en unknown
- 2010-04-12 LT LTEP12155472.9T patent/LT2497461T/lt unknown
- 2010-04-12 WO PCT/IB2010/051573 patent/WO2010122442A1/en active Application Filing
- 2010-04-12 MX MX2011010766A patent/MX337463B/es active IP Right Grant
- 2010-04-12 ES ES10717263T patent/ES2623936T5/es active Active
- 2010-04-12 CN CN2010800174060A patent/CN102405041A/zh active Pending
- 2010-04-20 TW TW099112270A patent/TWI429459B/zh active
- 2010-04-20 AR ARP100101299A patent/AR076338A1/es not_active Application Discontinuation
- 2010-12-04 UA UAA201112317A patent/UA107570C2/ru unknown
-
2011
- 2011-07-15 TN TN2011000350A patent/TN2011000350A1/fr unknown
- 2011-07-28 CO CO11095137A patent/CO6410278A2/es not_active Application Discontinuation
- 2011-08-15 IL IL214674A patent/IL214674A/en active IP Right Grant
- 2011-10-21 CL CL2011002634A patent/CL2011002634A1/es unknown
-
2014
- 2014-12-01 US US14/556,861 patent/US20150087719A1/en not_active Abandoned
-
2017
- 2017-05-31 CY CY20171100562T patent/CY1119390T1/el unknown
-
2018
- 2018-09-03 HR HRP20181408TT patent/HRP20181408T4/hr unknown
- 2018-09-07 CY CY181100939T patent/CY1120667T1/el unknown
-
2019
- 2019-07-25 AR ARP190102095A patent/AR117621A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR117621A2 (es) | UNA SOLUCIÓN ACUOSA SIN ALCOHOL ETÍLICO QUE COMPRENDE UN b-BLOQUEANTE Y DISPOSITIVO | |
| CO6270209A2 (es) | Un beta bloqueante para el tratamiento de los hemangiomas | |
| ES2537539T3 (es) | Composición oftálmica | |
| CY1122516T1 (el) | Ετοιμες προς χρηση διατυπωσεις κετορολακης | |
| UY30056A1 (es) | Administracion transdermica de meptazinol | |
| ECSP11011121A (es) | Sales de fingolimod | |
| CR9737A (es) | Dispositivos de administracion transdermicas de farmacos que contienen o-desmetilvenlafaxina (odv) sus sales. | |
| CL2009000533A1 (es) | Uso de una variante de defensina parenteral contra la tuberculosis; que comprende una sustitucion d9s en el polipeptido maduro; metodo para eliminar o inhibir mycobacterium in vitro. | |
| GT200500158A (es) | Derivados de amino-5,5-difenilimidazolona para la inhibicion de la b-secretasa | |
| PE20142372A1 (es) | Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico | |
| GT201200247A (es) | Formulaciones orales y sales lipofílicas de metilnaltrexona | |
| SV2008002984A (es) | Derivados de pirimidina utilizados como inhibidores de cinasa pi - 3 | |
| ES2570599T3 (es) | Composición suave para desinfección cutánea | |
| CR20120353A (es) | Método de tratamiento de la fibrilación auricular | |
| NI201400056A (es) | El uso de inhibidores de la actividad o función de la pi3k | |
| UY30901A (es) | Nuevos metodos | |
| BRPI0916540B8 (pt) | inibidores do canal de ânion de superficíe de plasmódio como agentes antimaláricos | |
| BR112014001118A2 (pt) | combinação tópica para aplicação oftálmica e uso de bimatoprost e brimonidina | |
| AR077125A1 (es) | Combinaciones farmaceuticas utiles para tratar el vhc | |
| AR054253A1 (es) | Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo | |
| CO6251249A2 (es) | Un medicamento que comprende un derivado un derivado de carbostirilo y donepezilo para tratar enfermedad de alzheimer | |
| CL2007002147A1 (es) | Bebida que tiene un contenido de energia total de menor a 4,06 kcal por 100 g y comprende 0,04 a 0,4% de catequinas (c)y un endulzante no nutritivo, donde la dulzura (s) es menor a 7% y se cumple la condicion 40<(s/c)<115; y uso de dicha bebida para el manejo del peso corporal. | |
| CR20140005A (es) | Una nueva composición terapéutica que contiene apomorfina como principio activo | |
| AR062401A1 (es) | Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis | |
| AR112482A1 (es) | Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |